EMBL-EBI | Chemical Biology | ChEBI
Example searches: iron*, InChI=1S/CH4O/c1-2/h2H,1H3, caffeine | Advanced Search
CHEBI:3437 - carteolol
| Formula | C16H24N2O3 |
| Net Charge | 0 |
| Average Mass | 292.379 |
| Monoisotopic Mass | 292.17869 |
| SMILES | CC(C)(C)NCC(O)COc1cccc2c1CCC(=O)N2 |
| InChI | InChI=1S/C16H24N2O3/c1-16(2,3)17-9-11(19)10-21-14-6-4-5-13-12(14)7-8-15(20)18-13/h4-6,11,17,19H,7-10H2,1-3H3,(H,18,20) |
| InChIKey | LWAFSWPYPHEXKX-UHFFFAOYSA-N |
| Wikipedia |
|---|
| Roles Classification |
|---|
| Biological Roles: | sympatholytic agent Any compound which inhibits the postganglionic functioning of the sympathetic nervous system (SNS). beta-adrenergic antagonist An agent that binds to but does not activate β-adrenergic receptors thereby blocking the actions of endogenous or exogenous β-adrenergic agonists. β-Adrenergic antagonists are used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, migraine headaches and anxiety. |
| Applications: | sympatholytic agent Any compound which inhibits the postganglionic functioning of the sympathetic nervous system (SNS). beta-adrenergic antagonist An agent that binds to but does not activate β-adrenergic receptors thereby blocking the actions of endogenous or exogenous β-adrenergic agonists. β-Adrenergic antagonists are used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, migraine headaches and anxiety. anti-arrhythmia drug A drug used for the treatment or prevention of cardiac arrhythmias. Anti-arrhythmia drugs may affect the polarisation-repolarisation phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibres. antihypertensive agent Any drug used in the treatment of acute or chronic vascular hypertension regardless of pharmacological mechanism. antiglaucoma drug Any drug which can be used to prevent or alleviate glaucoma, a disease in which the optic nerve is damaged, resulting in progressive, irreversible loss of vision. It is often, though not always, associated with increased pressure of the fluid in the eye. |
| ChEBI Ontology |
|---|
| Outgoing Relation(s) |
| carteolol (CHEBI:3437) has role anti-arrhythmia drug (CHEBI:38070) |
| carteolol (CHEBI:3437) has role antiglaucoma drug (CHEBI:39456) |
| carteolol (CHEBI:3437) has role antihypertensive agent (CHEBI:35674) |
| carteolol (CHEBI:3437) has role sympatholytic agent (CHEBI:66991) |
| carteolol (CHEBI:3437) has role β-adrenergic antagonist (CHEBI:35530) |
| carteolol (CHEBI:3437) is a quinolone (CHEBI:23765) |
| carteolol (CHEBI:3437) is a secondary alcohol (CHEBI:35681) |
| carteolol (CHEBI:3437) is conjugate base of carteolol(1+) (CHEBI:61202) |
| Incoming Relation(s) |
| carteolol(1+) (CHEBI:61202) is conjugate acid of carteolol (CHEBI:3437) |
| IUPAC Name |
|---|
| 5-[3-(tert-butylamino)-2-hydroxypropoxy]-3,4-dihydroquinolin-2(1H)-one |
| INNs | Source |
|---|---|
| carteolol | ChemIDplus |
| carteololum | WHO MedNet |
| cartéolol | WHO MedNet |
| carteolol | WHO MedNet |
| Synonym | Source |
|---|---|
| Carteolol | KEGG COMPOUND |